Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
Chronic Lymphocytic Leukemia (CLL) is one of the lymphoid neoplasms mainly affecting adults over age 55. Ibrutinib (Imbruvica) is currently the first-line therapy for various stages of CLL. It inhibits Bruton's Tyrosine Kinase (BTK). The most common adverse drug reactions include diarrhea, naus...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621921000168 |